XNCR Xencor Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: XNCR

Price (delayed)

$27.8

Market cap

$2.07B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$2.17

Enterprise value

$2.19B

?
Relative Growth: Rel. Growth: 27
Relative Strength: Rel. Strength: 98
Relative Valuation: Rel. Valuation: 7
Relative Profitability: Rel. Profitability: 37

Xencor is a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of patients with cancer and autoimmune diseases. More than 20 candidates engineered with Xencor's XmAb® technology are in ...

Highlights
Xencor's debt has decreased by 20% YoY and by 2.9% QoQ
The EPS has increased by 8% YoY and by 5% QoQ
The gross profit has decreased by 29% YoY but it has increased by 8% from the previous quarter
XNCR's revenue is down by 29% year-on-year but it is up by 8% since the previous quarter
XNCR's equity is down by 19% year-on-year and by 2.4% since the previous quarter
Sector: Healthcare
Industry: Biotechnology
Website: http://www.xencor.com
Peers: AMGN MGNX MRK ABBV

Key stats

What are the main financial stats of XNCR

XNCR stock price

How has the Xencor stock price performed over time
Intraday
2.96%
1 week
19.11%
1 month
35.94%
1 year
273.66%
YTD
81.58%
QTD
72.67%

Financial performance

How have Xencor's revenue and profit performed over time
Revenue
$104.97M
Gross profit
$104.97M
Operating income
-$216.08M
Net income
-$163.33M
Gross margin
100%
Net margin
-155.6%
XNCR's operating margin has dropped by 109% year-on-year but it is up by 6% since the previous quarter
Xencor's operating income has decreased by 49% YoY
Xencor's net margin has decreased by 34% YoY but it has increased by 12% QoQ
The gross profit has decreased by 29% YoY but it has increased by 8% from the previous quarter

Price vs fundamentals

How does XNCR's price correlate with its fundamentals

Growth

What is Xencor's growth rate over time

Valuation

What is Xencor stock price valuation
XNCR P/E details
P/E
N/A
P/B
4.1
P/S
20.09
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
20.88
The EPS has increased by 8% YoY and by 5% QoQ
XNCR's P/B is 128% above its last 4 quarters average of 1.8 and 95% above its 5-year quarterly average of 2.1
XNCR's equity is down by 19% year-on-year and by 2.4% since the previous quarter
XNCR's P/S is 126% above its 5-year quarterly average of 8.9 and 123% above its last 4 quarters average of 9.0
XNCR's revenue is down by 29% year-on-year but it is up by 8% since the previous quarter

Efficiency

How efficient is Xencor business performance
The ROS has decreased by 39% YoY but it has increased by 13% QoQ
The ROIC has contracted by 17% YoY
XNCR's ROE is down by 11% YoY
The ROA has contracted by 11% YoY

Dividends

What is XNCR's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for XNCR.

Financial health

How did Xencor financials performed over time
The company's current ratio rose by 20% YoY but it fell by 2.7% QoQ
XNCR's quick ratio is up by 19% year-on-year but it is down by 2.1% since the previous quarter
Xencor's debt is 66% lower than its equity
Xencor's debt has decreased by 20% YoY and by 2.9% QoQ
XNCR's equity is down by 19% year-on-year and by 2.4% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.